Terms: = Sarcomas AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
931 results:
1. HER3 (erbb3) amplification in liposarcoma - a putative new therapeutic target?
Becker AK; Puladi B; Xie K; Cassataro A; Götzl R; Hölzle F; Beier JP; Knüchel-Clarke R; Braunschweig T
World J Surg Oncol; 2024 May; 22(1):131. PubMed ID: 38760830
[TBL] [Abstract] [Full Text] [Related]
2. Development of a novel six DNA damage response-related prognostic signature in osteosarcoma.
Li T; Tang Z; Li S; Lu M
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):110-115. PubMed ID: 38650147
[TBL] [Abstract] [Full Text] [Related]
3. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract] [Full Text] [Related]
4. Elevated cobalt levels in metal-on-polyethylene knee megaprostheses: a prospective 1-year cohort study of 56 patients with hip and knee megaprostheses.
Freund SS; Thorn APJ; Puri A; Petersen MM; Baad-Hansen T
Acta Orthop; 2024 Apr; 95():174-179. PubMed ID: 38629902
[TBL] [Abstract] [Full Text] [Related]
5. Ferroptosis Altered microRNAs Expression in HT-1080 Fibrosarcoma Cells Based on Small RNA Sequencing and Bioinformatics Analysis.
Zhang Q; Wang Q; Ding H; Hu C; Feng J
Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542784
[TBL] [Abstract] [Full Text] [Related]
6. Targeting
Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
[TBL] [Abstract] [Full Text] [Related]
7. Red blood cells function as reservoirs of tumor DNA.
Thompson JC; Li S; Jose JS; Predina J; Gupta A; Eruslanov E; Singhal S; Albelda SM; Mangalmurti NS
Am J Physiol Lung Cell Mol Physiol; 2024 May; 326(5):L646-L650. PubMed ID: 38529551
[TBL] [Abstract] [Full Text] [Related]
8. Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less
Petterson J; Mustafa D; Bandaru S; Eklund EÄ; Hallqvist A; Sayin VI; Gagné A; Fagman H; Akyürek LM
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474205
[TBL] [Abstract] [Full Text] [Related]
9. Single-cell landscape of undifferentiated pleomorphic sarcoma.
Lu Y; Chen D; Wang B; Chai W; Yan M; Chen Y; Zhan Y; Yang R; Zhou E; Dai S; Li Y; Dong R; Zheng B
Oncogene; 2024 May; 43(18):1353-1368. PubMed ID: 38459120
[TBL] [Abstract] [Full Text] [Related]
10. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
[TBL] [Abstract] [Full Text] [Related]
11. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
12. Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?
Ma SS; Wang RR; Peng Q; Liu Y; Qian JY; Li MJ; Li K; Huang ZY; Wu LL; Xie D
Thorac Cancer; 2024 Mar; 15(9):715-721. PubMed ID: 38362771
[TBL] [Abstract] [Full Text] [Related]
13. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring egfr mutations was associated with a favorable prognosis to egfr-TKIs.
Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L
Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428
[TBL] [Abstract] [Full Text] [Related]
14. Novel KMT2B gene mutation in MUC4 positive low-grade fibromyxoid sarcoma.
Zhang L; Luo L; Liu C; Li Z
Diagn Pathol; 2024 Feb; 19(1):30. PubMed ID: 38347522
[TBL] [Abstract] [Full Text] [Related]
15. Cytotoxicity Enhancement in Osteosarcoma with Multifunctional I-131 Radiotherapeutic Nanoparticles: In Vitro Three-Dimensional Spheroid Model and Release Kinetics Modeling.
Marshall SK; Taweesap M; Saelim B; Pachana V; Benlateh N; Sangangam S; Bumrungsin A; Kholo-Asae H; Wongtechanon I
Molecules; 2024 Jan; 29(3):. PubMed ID: 38338373
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations.
Klubíčková N; Dermawan JK; Mosaieby E; Martínek P; Vaněček T; Hájková V; Ptáková N; Grossmann P; Šteiner P; Švajdler M; Kinkor Z; Michalová K; Szepe P; Plank L; Hederová S; Kolenová A; Spasov NJ; Kosemehmetoglu K; Pažanin L; Špůrková Z; Baník M; Baumruk L; Meyer A; Kalmykova A; Koshyk O; Michal M; Michal M
J Pathol; 2024 May; 263(1):61-73. PubMed ID: 38332737
[TBL] [Abstract] [Full Text] [Related]
17. The role of high mobility group AT-hook 1 in viral infections: Implications for cancer pathogenesis.
Akade E; Jalilian S
Int J Biochem Cell Biol; 2024 Apr; 169():106532. PubMed ID: 38278412
[TBL] [Abstract] [Full Text] [Related]
18. Utility of combining OLIG2 and SOX10 IHC expression in CNS tumours: promising biomarkers for subtyping paediatric- and adult-type gliomas.
Aboubakr O; Métais A; Maillard J; Hasty L; Brigot E; Berthaud C; Lacombe J; Pucelle N; Raynal J; Appay R; Varlet P; Tauziède-Espariat A
Histopathology; 2024 Apr; 84(5):893-899. PubMed ID: 38253970
[TBL] [Abstract] [Full Text] [Related]
19. Proteomics and genomics insights on malignant osteosarcoma.
Kathiresan N; Selvaraj C; Pandian S; Subbaraj GK; Alothaim AS; Safi SZ; Kulathaivel L
Adv Protein Chem Struct Biol; 2024; 138():275-300. PubMed ID: 38220428
[TBL] [Abstract] [Full Text] [Related]
20. Design, synthesis, and evaluation of dual egfr/AURKB inhibitors as anticancer agents for non-small cell lung cancer.
Kurup S; Gesinski D; Assaad K; Reynolds A
Bioorg Med Chem Lett; 2024 Mar; 100():129612. PubMed ID: 38199330
[TBL] [Abstract] [Full Text] [Related]
[Next]
